Sesen Bio Inc (SESN)

[umiak]

Cha ching! President and CEO (Stephen Hurly):

"2017 was a year of significant developments for our company, and as we look ahead, I am highly encouraged by what we have already achieved in 2018. Vicinium, our lead product candidate, holds significant potential in treating a range of cancers, and is well underway in a registration trial for people with non-muscle invasive bladder cancer. We recently completed enrollment in our Phase 3 VISTA trial, and we are pleased that initial data from the first patients were selected for an oral presentation at the American Urological Association Annual Meeting. 2018 is set to be a transformative year, and with the completion of our recent equity financing, we are capitalized to continue advancing Vicinium. We look forward to assessing its efficacy and safety in NMIBC, and exploring opportunities to expand its utility in other indications and in combination regimens." Presentation is 5/21/2018